Dorayshield recently announced a significant breakthrough – the successful delivery of ten tungsten alloy syringe shields, specifically designed for I-131 drug injections, to a renowned US university medical laboratory. This marks international recognition of the company's technological strength in nuclear medicine protective equipment and also serves as a key step in its overseas market expansion.
The tungsten syringe shields being exported are core products of Dorayshield, designed for the clinical aspects of nuclear medicine. A common radioactive therapeutic agent, I-131, is used for the treatment of various thyroid diseases. Radiation, which is a by-product of the I-131 treatment, if not properly shielded, can cause harm to the medical staff and the surrounding environment. A tungsten alloy syringe shield has a casing made of tungsten alloy, which is used to form the syringe. I-131 is easily shielded by tungsten alloy’s high density and exceptional radiation shielding capabilities. I-131 shields are significantly more effective than conventional lead shielding. Additionally, the syringe's deformed shape makes it more rigid and lighter, which increases the convenience for the medical staff. Precision of the syringe’s programmable injection mechanism has been achieved through extensive calibration, controlling the treatment through automated systems to eliminate operational shortfalls. It meets the rigid requirements of the nuclear medicine apparatus from the US.
According to the company's head of R&D, this collaboration stemmed from a specific need at a US university's medical laboratory. The laboratory, which has long researched radiotherapy for thyroid disease, was in urgent need of more reliable equipment due to the unstable shielding effect and cumbersome operation of its previous syringe shields. After learning about Dorayshield products through industry academic discussions, the laboratory conducted three months of performance testing on samples. The results demonstrated that the tungsten alloy syringe shields achieved a radiation shielding rate exceeding 99.8% and significantly improved operation efficiency compared to the existing equipment. The laboratory ultimately decided to purchase ten units for clinical research and treatment.
This accomplishment about the U. S. is evidence of the remarkable technological prowess of Dorayshield, which allows the firm to begin selling its nuclear medicine protection equipment to the North America region. In the future, the firm will continue to broaden its knowledge and understanding of nuclear medicine and develop tailored shielding equipment to cross different kinds of therapeutic radiopharmaceuticals. This will, at a global scale, enhance the way nuclear medicine is treated and will, more importantly, provide medical businesses access to devices that are more effective, safe, and easy to use.